Executive Functioning in Pediatric Anxiety and Its Relationship to Selective Serotonin Reuptake Inhibitor Treatment Response: A Double-Blind, Placebo-Controlled Trial.

To characterize executive function in adolescents with generalized anxiety disorder (GAD) and its relationship to treatment. Using data from a double-blind, placebo-controlled trial of escitalopram in adolescents ( = 51) 12-17 years of age with GAD, we used the self-report version of the Behavior Rating Inventory of Executive Function (BRIEF-SR) to assess executive function, at baseline, and examined its relationship to treatment response as measured by the Pediatric Anxiety Rating Scale (PARS). For all baseline subscores of the BRIEF-SR, T-scores were significantly elevated in adolescents with GAD compared to an age- and sex-matched normative healthy sample. In escitalopram-treated patients, baseline BRIEF-SR scores for Emotional Control ( = 0.256, 95% credibility interval [CrI]: 0.367 to 0.146,  < 0.001), Working Memory ( = 0.204, CrI: 0.2952 to 0.1134,  < 0.001), Planning/Organizing ( = 0.223, CrI: -0.1021 to -0.3436,  = 0.004), and Task Completion ( = -0.152, CrI: 0.075 to 0.228,  = 0.002) predicted the trajectory of improvement in PARS score over the 8-week trial. For youth who received placebo, only the Inhibit score was significantly, but weakly, associated with response trajectory ( = -0.081, CrI: -0.0167 to -0.1461,  = 0.015). For adolescents who had clinically significant impairment in Emotional Control, Working Memory, Planning/Organizing, and Task Completion (i.e., T-score >65), the trajectory of improvement significantly differed from patients without scores in the clinically significant range. Taken together, these findings point to the potential value of assessing executive function in youth with anxiety disorders as one strategy for guiding treatment selection. These data suggest that executive function may predict treatment response to psychopharmacologic treatment and point to numerous avenues for further personalizing treatment.